ILiAD Biotechnologies
PrivateLast Round
Series B
Feb 10, 2026
Est. Valuation
$176M
Total Funding Raised
$219.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ILiAD Biotechnologies is a biotechnology company that develops a medical vaccine aimed at preventing and treating diseases caused by Bordetella pertussis by inducing the immune system to produce protective antibodies against infections like whooping cough.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ILiAD Biotechnologies Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
ILiAD Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 10, 2026 | ||||
| Series D | Sep 6, 2022 | ||||
| Grant | Apr 26, 2022 | ||||
| Convertible Debt | Mar 12, 2021 | ||||
| Series C | Dec 19, 2018 | ||||
Grant | Jul 5, 2017 |
Key People
Founding team and executive leadership
ILiAD Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series B |
| RA Capital Management | Series B |
| National Institute of Allergy and Infectious Diseases | Grant |
| Knott Partners, LP | Series D |
| Network-1 Technologies | Convertible Debt, Series C |
| SDS Capital Partners | Series C |
| Seedlings Life Science Ventures | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 16, 2026
Grew 17% QoQ, from 24 to 28 employees.
- Apr 20, 2026
Monthly visitors increased 87% MoM.
ILiAD Biotechnologies Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ILiAD Biotechnologies's valuation, stock price, and market status.